MX350206B - Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle). - Google Patents

Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).

Info

Publication number
MX350206B
MX350206B MX2012006197A MX2012006197A MX350206B MX 350206 B MX350206 B MX 350206B MX 2012006197 A MX2012006197 A MX 2012006197A MX 2012006197 A MX2012006197 A MX 2012006197A MX 350206 B MX350206 B MX 350206B
Authority
MX
Mexico
Prior art keywords
treatment
sle
antibodies
lupus erythematosus
systemic lupus
Prior art date
Application number
MX2012006197A
Other languages
English (en)
Other versions
MX2012006197A (es
Inventor
Bruecher Christoph
Daelken Benjamin
Osterroth Frank
Uherek Christoph
Wartenberg Demand Andrea
Zuber Chantal
Czeloth Niklas
Engling Andre
Roettgen Peter
Gutscher Marcus
Wessels Kranz Judith
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of MX2012006197A publication Critical patent/MX2012006197A/es
Publication of MX350206B publication Critical patent/MX350206B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo humanizado o su fragmento capaz de ligar a interleucina-10 (IL-10), caracterizado porque el anticuerpo o su fragmento comprende una cadena ligera variable que comprende las secuencias de aminoácidos de SEQ ID NO: 71, 72, y 73, y una cadena pesada variable que comprende las secuencias de aminoácidos de SEQ ID NO: 74, 75 Y 76.
MX2012006197A 2009-11-30 2010-11-30 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle). MX350206B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
PCT/EP2010/068562 WO2011064398A1 (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Publications (2)

Publication Number Publication Date
MX2012006197A MX2012006197A (es) 2012-06-19
MX350206B true MX350206B (es) 2017-08-28

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012006197A MX350206B (es) 2009-11-30 2010-11-30 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).
MX2012006198A MX343228B (es) 2009-11-30 2010-11-30 Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012006198A MX343228B (es) 2009-11-30 2010-11-30 Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.

Country Status (17)

Country Link
US (4) US8956607B2 (es)
EP (2) EP2470209B1 (es)
JP (2) JP6005519B2 (es)
KR (2) KR101802261B1 (es)
CN (2) CN102811736B (es)
AU (2) AU2010323037B2 (es)
BR (2) BR112012012912A2 (es)
CA (2) CA2782007C (es)
CO (1) CO6561779A2 (es)
CR (2) CR20120358A (es)
IL (2) IL219954A (es)
MX (2) MX350206B (es)
NZ (2) NZ600894A (es)
RU (2) RU2587622C2 (es)
SG (2) SG10201407936XA (es)
WO (2) WO2011064398A1 (es)
ZA (1) ZA201204843B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102811736B (zh) * 2009-11-30 2016-01-20 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
CA2928710A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2017512056A (ja) * 2014-02-10 2017-05-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・タウに結合する抗体および該抗体を使用してヒト・タウを定量するためのアッセイ
JP2017535783A (ja) * 2014-11-28 2017-11-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ センサー表面でアナライト−リガンド結合を測定するための方法
CA2970759A1 (en) * 2014-12-15 2016-06-23 Morphosys Ag Antibodies for il-17c
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
CN108602870A (zh) 2015-12-04 2018-09-28 诺华股份有限公司 抗体细胞因子嫁接组合物及用于免疫调节的方法
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
IL305969A (en) * 2021-03-23 2023-11-01 Organogenesis Inc Kits and composition methods for characterizing the anti-inflammatory response of a product
KR20240114801A (ko) * 2023-01-17 2024-07-25 한양대학교 산학협력단 Il-10 수용체에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0495639A1 (en) 1991-01-16 1992-07-22 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
CZ281796B6 (cs) 1991-08-06 1997-02-12 Schering Corporation Použití interleukinu-10, jeho analoga, agonisty nebo antagonisty pro výrobu léčiva a farmaceutický přípravek je obsahující
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
MXPA05006511A (es) * 2002-12-16 2006-02-17 Genentech Inc Variantes de inmunoglobulina y sus usos.
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp ANTI-INTERLEUKIN ANTIBODY-10
CN104017079B (zh) 2007-08-29 2017-01-04 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
CN102811736B (zh) * 2009-11-30 2016-01-20 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体

Also Published As

Publication number Publication date
EP2470209B1 (en) 2020-01-01
CN102711829B (zh) 2016-03-16
US8852871B2 (en) 2014-10-07
US9605066B2 (en) 2017-03-28
IL219955A (en) 2016-08-31
JP2013511994A (ja) 2013-04-11
NZ600894A (en) 2014-09-26
CR20120359A (es) 2013-01-25
RU2581812C2 (ru) 2016-04-20
NZ600899A (en) 2014-09-26
AU2010323037B2 (en) 2015-01-29
RU2012127381A (ru) 2014-01-10
RU2012127380A (ru) 2014-01-10
US20150064179A1 (en) 2015-03-05
JP2013511995A (ja) 2013-04-11
CN102711829A (zh) 2012-10-03
IL219954A (en) 2016-10-31
AU2010323036B2 (en) 2015-01-29
EP2470209A1 (en) 2012-07-04
MX2012006197A (es) 2012-06-19
SG10201407935YA (en) 2015-01-29
BR112012012917A2 (pt) 2016-10-25
CN102811736A (zh) 2012-12-05
MX343228B (es) 2016-10-26
WO2011064398A1 (en) 2011-06-03
EP2470208A1 (en) 2012-07-04
US20120321617A1 (en) 2012-12-20
CA2782004A1 (en) 2011-06-03
IL219955A0 (en) 2012-07-31
CO6561779A2 (es) 2012-11-15
US20120321618A1 (en) 2012-12-20
AU2010323037A1 (en) 2012-07-19
US9540436B2 (en) 2017-01-10
KR101802261B1 (ko) 2017-11-28
KR20120115289A (ko) 2012-10-17
SG10201407936XA (en) 2015-01-29
ZA201204843B (en) 2020-02-26
US20150218270A1 (en) 2015-08-06
US8956607B2 (en) 2015-02-17
BR112012012912A2 (pt) 2016-10-25
WO2011064399A1 (en) 2011-06-03
CR20120358A (es) 2013-01-23
CA2782007A1 (en) 2011-06-03
RU2587622C2 (ru) 2016-06-20
JP6005519B2 (ja) 2016-10-12
KR101802260B1 (ko) 2017-11-28
IL219954A0 (en) 2012-07-31
AU2010323036A1 (en) 2012-07-19
CA2782007C (en) 2018-07-24
KR20120103664A (ko) 2012-09-19
MX2012006198A (es) 2012-06-19
CN102811736B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
MX350206B (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).
HRP20181245T1 (hr) Anti-cd38 protutijela
MX2013009362A (es) Anticuerpo contra el csf-1r.
WO2015091914A3 (en) Caninized murine anti-canine pd-1 antibodies
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
NZ607969A (en) Cd33 binding agents
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
NZ724296A (en) Antibodies for treatment of cancer expressing claudin 6
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
PT2768857T (pt) Métodos para purificar anticorpos
MX343659B (es) Proteínas de unión receptoras fc.
MX2013011385A (es) Moleculas de union a cd37 y sus inmunoconjugados.
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
SG11201507686TA (en) Pan-ELR<sp>+</sp> CXC CHEMOKINE ANTIBODIES
DK2623592T3 (da) Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
WO2012097238A3 (en) Il-27 antagonists for treating inflammatory diseases
SG10201901695RA (en) Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
IL277056A (en) Methods for purifying antibodies
SG11202112846RA (en) Methods for purifying antibodies
WO2013082342A3 (en) Apparatus and method for carbon activation using multi-chamber periodic furnace
Qi-Guang et al. The Relationship between Family and School Reform: the Experience of the West and China's Problem
UA71235U (uk) СПОСІБ ОТРИМАННЯ НАНОСТРУКТУР ZnO

Legal Events

Date Code Title Description
FG Grant or registration